Quote this publication Share Print

Clinical utility of genomic signatures in early-stage breast cancer - INAHTA Brief

Health technology assessment - Posted on Feb 11 2019

Evaluate the clinical utility of four genomic signatures (GS)[1], currently and temporarily funded on a conditional basis as part of a specific funding program for research and innovation (known in France as RIHN). The aim of the evaluation is to assess funding eligibility for the traditional reimbursement schemes offered by the National Health Insurance Fund.



[1] Oncotype Dx, Mammaprint (first generation GS tests), Endopredict, Prosigna (second generation GS tests).

Contact Us

Évaluation des actes professionnels

See also